EBR Systems, Inc. news
- EBR Systems’ WiSE™ CRT System is world’s first and only wireless endocardial (inside the heart) left ventricle pacing system for heart failure
- EBR’s AU$110m ASX initial public offering today was strongly supported by new and existing institutional shareholders
- The new capital funds the completion of pivotal study, targeting FDA submission for approval in 2023 followed by rapid U.S. commercial lau
Highlights:
- Dr Evans, Dr Steinhaus and Ms Drexler to join EBR Systems’ Board ahead of the planned A$110m IPO on the Australian Stock Exchange
- Board appointments follow the retirement of Mr Dave Stassen and Dr Leighton Read
- New EBR Systems’ Board consists of Mr Allan Will, Mr John McCutcheon, Dr Christopher Nave, Mr Trevor Moody, Dr Bronwyn Evans, Dr David Steinhaus and Ms Karen Drexler
Published last month in the European Heart Journal, the case report details the successful deployment of the WiSE Electrode implanted in the LV
EBR Systems, Inc., developer of the world’s only wireless cardiac pacing system for heart failure, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the WiSE CRT System for the treatment of heart failure.
The FDA created this designation and its associated program in 2017 for certain devices providing more effective treatment of life-threatening or irreversibly debilitating diseases or conditions. Under
EBR Systems, Inc., developer of the world’s only wireless cardiac pacing system for heart failure, today announced that Professor Pascal Defaye, Head of Rhythmology and Cardiac Stimulation Unit, CHU de Grenoble-Alpes, France, performed the world’s first successful Leadless Left Bundle Branch Area Pacing (LBBAP) implant performed utilizing the WiSE CRT System.
LBBAP pacing has been proposed as a strategy to achieve physiological pacing by utilizing the heart&rs